Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside Denes V. Agoston Department of Anatomy, Physiology and Genetics, Uniformed Services University, Bethesda, MD, United States Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the BedsideFluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside International Journal of Molecular ScienceInternational Journal of Molecular Science We review the current status of biomarker research and discuss how we can integrate existing markers into current clinical practice and what additional biomarkers do we need to improve diagnoses and to guide therapy and to assess treatment efficacy. Furthermore, we argue for employing machine learning (ML) capabilities to integrate the protein biomarker data with other established, routinely used clinical

Editorial: When Physics Meets Biology; Biomechanics and Biology of Traumatic Brain Injury Denes V. Agoston Department of Anatomy, Physiology and Genetics, Uniformed Services University, Bethesda, MD, United States Traumatic brain injury (TBI) has been referred to as the “silent epidemic” but given its substantial and recurring impact on global health, it should be renamed to the “silent pandemic”. The COVID-19 pandemic has majorly impacted biomedical research of TBI; experimental and clinical studies have either slowed or halted and resources have been reallocated, thus resulting in a “lost year” for the TBI field. However, the pandemic can serve as an inflection point. The conceptual and technical lessons that can be learned from COVID-19 and could lead to clearer classification, improved diagnosis,

COVID-19 and Traumatic Brain Injury (TBI); What We Can Learn From the Viral Pandemic to Better Understand the Biology of TBI, Improve Diagnostics and Develop Evidence-Based Treatments Denes V. Agoston Department of Anatomy, Physiology and Genetics, Uniformed Services University, Bethesda, MD, United States Traumatic brain injury (TBI) has been referred to as the “silent epidemic” but given its substantial and recurring impact on global health, it should be renamed to the “silent pandemic”. The COVID-19 pandemic has majorly impacted biomedical research of TBI; experimental and clinical studies have either slowed or halted and resources have been reallocated, thus resulting in a “lost year” for the TBI field. However, the pandemic can serve as an inflection point. The conceptual and technical